Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minamiku, Hiroshima, 734-8551, Japan.
Department of Neurosurgery, Izumi Regional Medical Center, Izumi, Japan.
Endocrine. 2021 Jul;73(1):151-159. doi: 10.1007/s12020-020-02556-2. Epub 2020 Dec 7.
Thyrotropin-secreting pituitary adenomas (TSPA) are extremely rare pituitary adenomas; their perioperative thyroid hormone dynamics have not been completely elucidated. Here, we investigated the clinical characteristics, perioperative findings, and thyroid hormone dynamics of TSPA at a single institution.
We enrolled 11 patients who underwent transsphenoidal surgery (TSS) for TSPA during 2005-2019 at Hiroshima University Hospital (TSPA group) and 24 patients who underwent TSS for nonfunctioning pituitary adenomas (NFPA) in 2019 (NFPA group; for comparison). Their clinical characteristics, operative findings, and thyroid hormone dynamics, including serum thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4), were retrospectively analyzed.
The NFPA group demonstrated a slight temporary decrease in serum TSH/ FT3/ FT4 levels on day 1 postoperatively and improvement in the levels on day 4 postoperatively. In contrast, the serum TSH level in the TSPA group demonstrated a marked decrease on day 1 postoperatively but improved on day 7 postoperatively. The serum FT3 level was also markedly decreased on day 1 postoperatively but remained within the normal range. The serum FT4 level revealed a gradual decrease until day 21 postoperatively and then recovered within the normal range 3 months postoperatively. There was no significant difference in the frequency of decline in serum FT4 level between the two groups; no patients required thyroid hormonal replacement 3 months postoperatively.
Despite a variable degree of transient hypothyroidism, all patients had a normal thyroid function after 3 months follow-up.
促甲状腺激素分泌垂体腺瘤(TSPA)是极为罕见的垂体腺瘤;其围手术期甲状腺激素动态尚未完全阐明。在这里,我们在单家机构研究了 TSPA 的临床特征、围手术期发现和甲状腺激素动态。
我们纳入了 2005 年至 2019 年在广岛大学医院接受经蝶窦手术(TSS)治疗 TSPA 的 11 例患者(TSPA 组)和 2019 年接受 TSS 治疗无功能垂体腺瘤(NFPA)的 24 例患者(NFPA 组;作为比较)。回顾性分析了他们的临床特征、手术发现和甲状腺激素动态,包括血清促甲状腺激素(TSH)、游离三碘甲状腺原氨酸(FT3)和游离甲状腺素(FT4)。
NFPA 组术后第 1 天血清 TSH/FT3/FT4 水平略有短暂下降,第 4 天恢复正常。相比之下,TSPA 组术后第 1 天血清 TSH 水平显著下降,但第 7 天恢复正常。血清 FT3 水平也在术后第 1 天明显下降,但仍在正常范围内。血清 FT4 水平逐渐下降,直到术后第 21 天,然后在术后 3 个月内恢复正常。两组患者血清 FT4 水平下降的频率无显著差异;术后 3 个月无患者需要甲状腺激素替代治疗。
尽管存在不同程度的一过性甲状腺功能减退症,但所有患者在 3 个月随访后甲状腺功能均正常。